ESPERION THERAPEUTICS INC (ESPR) Stock Price, Forecast & Analysis
USA - NASDAQ:ESPR - US29664W1053 - Common Stock
ESPR Key Statistics, Chart & Performance
The current stock price of ESPR is 2.5 USD. In the past month the price increased by 2.24%. In the past year, price increased by 10.09%.
ESPR Latest News, Press Relases and Analysis
ESPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.63 | 887.25B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.29B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.87 | 259.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.14 | 245.02B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 11.86 | 206.66B | ||
| MRK | MERCK & CO. INC. | 9.74 | 214.26B | ||
| PFE | PFIZER INC | 7.77 | 141.29B | ||
| SNY | SANOFI-ADR | 11.32 | 120.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.91B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 94.73B | ||
| ZTS | ZOETIS INC | 18.86 | 52.99B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 194.86 | 43.08B |
Related stock screener links
About ESPR
Company Profile
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Company Info
ESPERION THERAPEUTICS INC
3891 Ranchero Drive, Suite 150, Suite 300
Ann Arbor MICHIGAN 48108 US
CEO: Tim M. Mayleben
Employees: 304
Phone: 17348873903
ESPERION THERAPEUTICS INC / ESPR FAQ
What does ESPERION THERAPEUTICS INC do?
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
What is the stock price of ESPERION THERAPEUTICS INC today?
The current stock price of ESPR is 2.5 USD. The price decreased by -14.97% in the last trading session.
Does ESPR stock pay dividends?
ESPR does not pay a dividend.
What is the ChartMill rating of ESPERION THERAPEUTICS INC stock?
ESPR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does ESPERION THERAPEUTICS INC have?
ESPERION THERAPEUTICS INC (ESPR) currently has 304 employees.
What is the ownership structure of ESPERION THERAPEUTICS INC (ESPR)?
You can find the ownership structure of ESPERION THERAPEUTICS INC (ESPR) on the Ownership tab.
Can you provide the short interest for ESPR stock?
The outstanding short interest for ESPERION THERAPEUTICS INC (ESPR) is 10.57% of its float.
ESPR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ESPR. When comparing the yearly performance of all stocks, ESPR is one of the better performing stocks in the market, outperforming 85.41% of all stocks.
ESPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ESPR. Both the profitability and financial health of ESPR have multiple concerns.
ESPR Financial Highlights
Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 43.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ESPR Forecast & Estimates
14 analysts have analysed ESPR and the average price target is 6.39 USD. This implies a price increase of 155.68% is expected in the next year compared to the current price of 2.5.
For the next year, analysts expect an EPS growth of 97.14% and a revenue growth 19.21% for ESPR